<div id="readability-page-1"><div> , /PRNewswire/ -- At first glance, Finland's M&amp;A market appeared stagnant in 2025. A closer look, however, reveals a more nuanced picture: while the number of completed transactions remained broadly unchanged, aggregate deal value increased materially. Capital did not leave the market - instead, it became more selective, concentrating on fewer but strategically critical assets, particularly in infrastructure, healthcare and care services. A total of 579 transactions were completed in Finland in 2025, virtually unchanged from 580 deals the previous year. Activity neither accelerated nor collapsed, which is notable given the backdrop of weak economic growth, elevated unemployment and persistent uncertainty.By contrast, total deal value increased by approximately 20%, rising to an estimated EUR 12.5 billion from EUR 10.5 billion in 2024 (source: Mergermarket). The increase suggests renewed willingness among investors to execute larger, more strategic transactions despite challenging macroeconomic conditions.According to Carner Corporate Finance, the data points to a clear shift in market focus - from volume to quality.&#34;The market was not particularly active, but it was highly deliberate. Buyers were not pursuing deals for the sake of activity; instead, they focused on profitability, cash flow resilience and clear strategic fit,&#34; says Mikko Sistonen, Partner at Carner Corporate Finance.While deal value remained well below the 2023 peak of EUR 17.8 billion, the direction was encouraging. A full return to peak levels has not yet materialised, but the underlying dynamics have begun to normalise.Large, strategic transactions stood outThe Finnish M&amp;A market in 2025 was shaped by a limited number of large, structurally significant transactions.The most prominent was Hellman &amp; Friedman's investment in Mehiläinen, reinforcing the attractiveness of healthcare and care services even amid economic uncertainty. Predictable cash flows, demographic tailwinds and scalable operating models continue to appeal to long-term investors.Another notable transaction was the divestment of Tietoevry's Tech Services business and the creation of Vivicta as a standalone company. The transaction reflected a broader M&amp;A logic visible across the market: sharpening strategic focus through carve-outs and unlocking growth potential outside large corporate group structures.Infrastructure also emerged as a key theme. Triton Partners' formation of Lohkare Infra Oy - consolidating several Finnish infrastructure companies into a new platform - was not a single transaction but a clear signal of consolidation potential and long-term conviction in the sector.Macroeconomic pressure increased selectivityThroughout 2025, M&amp;A activity was shaped by a challenging macroeconomic environment. Finland's GDP growth hovered between 0.2% and 0.5%, while unemployment rose above 10%, among the highest levels in Europe.These conditions increased selectivity on both sides of the market. Many potential sellers were unwilling to exit in a weak cycle, while buyers applied increasingly stringent investment criteria.Buyers were looking for quality. In 2025, companies with proven profitability and a clearly defined role in the buyer's strategy stood out. Growth narratives alone were no longer sufficient, Sistonen adds.Laying the groundwork for the next cycleCarner Corporate Finance views 2025 as a transitional year in Finland's M&amp;A cycle. The market did not yet return to full momentum, but it clearly moved away from stagnation, adapting to a new operating environment and laying the foundations for the next upturn.Private equity investors continue to hold significant amounts of dry powder, and strategic buyers are positioning themselves to capitalise on a recovery once economic visibility and confidence improve. The timing of a more pronounced rebound will depend largely on developments in Finland's economy and labour market - and, above all, on the restoration of confidence.The market was not frozen, even if it initially appeared so. 2025 marked a step away from uncertainty, though not yet a return to full speed, Sistonen concludes.For additional information, please contact:Mikko Sistonen Partner Carner Corporate Finance +358 50 593 7303 mikko.sistonen@carner.com This information was brought to you by Cision http://news.cision.comhttps://news.cision.com/carner-corporate-finance/r/finnish-m-a-deal-value-rose-20--despite-unchanged-transaction-volumes,c4296115The following files are available for download:<div><table><tbody><tr><td colspan="1" rowspan="1">https://news.cision.com/carner-corporate-finance/i/carner-corporate-finance,c3503446</td><td colspan="1" rowspan="1">Carner Corporate Finance</td></tr></tbody></table></div> <img width="12" height="12" src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wMS0yMiZzbj1JTzY4OTI4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wMS0yMiZzbj1JTzY4OTI4"/> View original content:https://www.prnewswire.com/news-releases/finnish-ma-deal-value-rose-20-despite-unchanged-transaction-volumes-carner-corporate-finance-302667790.htmlSOURCE Carner Corporate Finance</div></div>

In 2025, Finland's M&A market saw a 20% increase in total deal value, rising to EUR 12.5 billion, despite transaction volumes remaining stable at 579 deals. Investors became more selective, focusing on strategic assets in infrastructure and healthcare. Notable transactions included Hellman & Friedman's investment in Mehiläinen and the divestment of Tietoevry's Tech Services. The challenging macroeconomic environment, with GDP growth between 0.2% and 0.5% and unemployment over 10%, influenced buyer selectivity. Carner Corporate Finance views 2025 as a transitional year, setting the stage for future recovery in the M&A landscape.

fidelity

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Ark Genomic Revolution ETF

Penghua CSI HK Connect Health Care Composite ETF

iShares Global Healthcare

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Guotai CSI Bio-medicine ETF

Invesco Nasdaq Biotechnology ETF

VG Health

Yinhua CSI Research Sector 100 ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

China Merchants CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Huaan Hang Seng Biotech ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Health Care Select Sector SPDR

Penghua SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

Bosera Hang Seng Health Care ETF(QDII)

E Fund CSI Biotechnology Theme ETF

iShares Biotechnology ETF

Yinhua CSI Innovative Drugs Industry ETF

China Southern Hang Seng Biotech ETF(QDII)

E Fund CSI 300 Health Care ETF

Hwabao WP CSI Pharmaceuticals ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Ping An CSI Medicine and Medical Device Innovation ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

iShares US Pharma

E Fund Hang Seng SCHK Innovative Drug ETF

Finnish M&A deal value rose 20% despite unchanged transaction volumes: Carner Corporate Finance